Traumatic dermatosis inhibitor, skin collagen production promoter, skin harmful bacteria proliferation inhibitor, and medicine, cosmetic and food product containing these
Kestose-based agents address the lack of understanding in traumatic skin disease management by suppressing diseases, inhibiting harmful bacteria, and promoting collagen production, enhancing skin health.
Patent Information
- Application Number
- JP2023078012
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-10
- Publication Date
- 2024-11-21
AI Technical Summary
Existing technologies have not elucidated the effects of kestose on traumatic skin diseases caused by external physical stimuli, and there is a lack of understanding of its impact on skin collagen production and harmful bacterial growth.
Development of agents containing kestose as an active ingredient to suppress traumatic skin diseases, inhibit harmful bacterial growth, and promote skin collagen production, utilizing kestose's novel efficacy.
Kestose effectively suppresses traumatic skin diseases, inhibits harmful bacterial growth, and promotes skin collagen production, improving skin health and reducing disease progression.
Smart Images

Figure 2024162475000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to an agent for suppressing traumatic skin diseases, an agent for promoting skin collagen production, an agent for suppressing the proliferation of harmful skin bacteria, and medicines, cosmetics and foods containing these. [Background technology]
[0002] Kestose reaches the lower digestive tract without being broken down or absorbed in the upper digestive tract, where it serves as a selective substrate for beneficial bacteria (good bacteria) that live symbiotically in the large intestine, promoting their growth and activating their metabolism, thereby improving or maintaining a healthy balance of the intestinal flora and inducing beneficial effects on human health. It is known as a prebiotic.
[0003] Patent Document 1 (JP Patent Publication No. 2006-321786) describes the allergy suppressing effect of ingesting the prebiotic kestose (1-kestose). [Prior art documents] [Patent documents]
[0004] [Patent Document 1] JP 2006-321786 A [Patent Document 2] Japanese Patent Application Publication No. 58-201980 [Patent Document 3] JP 2000-232878 A [Patent Document 4] Special Publication No. 6-70075 [Patent Document 5] Patent Publication No. 2021-040517 [Patent Document 6] JP 2020-094047 A [Non-patent literature]
[0005] [Non-Patent Document 1] Takumi Tochio, Kanako Minoda, Shigeo Watanabe, "Functions of the Functional Oligosaccharide 1-Kestose and the Oligosaccharide Food "Baby Oligo (Registered Trademark)"," Food and Development, Informa Markets Japan Co., Ltd., December 2014, Vol. 49, No. 12, p. 8-10 Summary of the Invention [Problem to be solved by the invention]
[0006] Here, an allergic reaction is an excessive immune response to an allergen, and although the allergen itself is a foreign antigen, the intrinsic immunity that causes an excessive reaction to the allergen can be regarded as an allergic reaction factor.
[0007] So far, the beneficial effects of kestose on endogenous diseases caused by endogenous factors such as allergies have been known, as exemplified in Patent Document 1. On the other hand, for example, the effect of kestose on exogenous diseases caused by external (outside the body) physical stimuli has not been elucidated at all. [Means for solving the problem]
[0008] Therefore, the present inventors studied the effect of kestose on traumatic skin diseases as "exogenous diseases" and further developed the research to study the effect of kestose on harmful bacteria that progress and aggravate traumatic skin diseases, as well as the effect of kestose on skin collagen that creates robust skin. As a result, they discovered a completely new efficacy of kestose that had not been known before, leading to the present invention.
[0009] That is, an object of the present invention is to provide an agent that utilizes a novel, hitherto unknown efficacy of kestose.
[0010] The present invention solves the above problems by the means described below as one embodiment.
[0011] One embodiment of the present invention is a traumatic skin disease inhibitor containing kestose as an active ingredient.
[0012] Another embodiment of the present invention is an inhibitor of the proliferation of harmful skin bacteria, which contains kestose as an active ingredient.
[0013] Another embodiment of the present invention is a skin collagen production promoter containing kestose as an active ingredient. Effect of the Invention
[0014] According to the present invention, by using kestose as an active ingredient, it is possible to suppress traumatic skin diseases. Also, according to the present invention, by using kestose as an active ingredient, it is possible to suppress the proliferation of harmful skin bacteria, and suppress an increase in their number or reduce their number. Also, according to the present invention, by using kestose as an active ingredient, it is possible to promote the production of skin collagen, and suppress a decrease in its amount or increase its amount. Kestose can promote the production of skin collagen regardless of the presence or absence of skin diseases. [Brief description of the drawings]
[0015] [Figure 1] FIG. 1 is a bar graph showing the quantified area of pressure ulcers in the control group and the example group one day after the skin pressure was released from the mice. [Diagram 2] Fig. 2A is an electron microscope image of a specimen stained with Masson's trichrome on a tissue section taken from a pressure ulcer in a mouse in the control group one day after skin pressure was released. Fig. 2B is an electron microscope image of a specimen stained with Masson's trichrome on a tissue section taken from a pressure ulcer in a mouse in the example group one day after skin pressure was released. [Diagram 3] Fig. 3A is an electron microscope image of a Tunel-stained tissue section taken from a pressure ulcer in a control mouse one day after skin pressure was released. Fig. 3B is an electron microscope image of a Tunel-stained tissue section taken from a pressure ulcer in a control mouse one day after skin pressure was released. [Figure 4]Fig. 4A is a bar graph showing the quantified collagen fiber area (collagen deposition) in specimens stained with Masson's Trichrome from tissue sections taken from normal mouse skin in the control and experimental groups, and Fig. 4B is a bar graph showing the thickness of the dermis where the collagen layer is formed. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] Hereinafter, an embodiment of the present invention will be described.
[0017] The first embodiment of the present invention is a traumatic skin disease inhibitor containing kestose as an active ingredient. This embodiment is an agent that utilizes the novel efficacy of kestose, which exerts a beneficial effect in inhibiting traumatic skin diseases. The "inhibitory effect of traumatic skin diseases" referred to here includes a preventive effect of inhibiting the onset of a disease by taking kestose before the onset of a skin disease, an effect of inhibiting the progression and worsening of an inflammation that has already developed, and an effect of promoting the alleviation and improvement of inflammation as a result.
[0018] As described above, the traumatic skin disease to which the present embodiment is applicable is one of the exogenous diseases caused by external (outside the body) physical stimuli, unlike endogenous diseases caused by endogenous factors (immunity) such as allergies. Specifically, examples of traumatic skin diseases include bedsores, burns, cuts, abrasions, contusions, crush wounds, puncture wounds, bites, surgical wounds, and other wounds. Hereinafter, in this specification, bedsores will be used as an example of traumatic skin diseases to explain the present invention.
[0019] According to the Japan Society of Pressure Ulcers, "pressure ulcers are caused by poor or stagnant blood flow in areas of the skin that are compressed by body weight due to being bedridden, causing redness, sores, or scars" (http: / / www.jspu.org / jpn / patient / about.html), and are generally also called "bedsores." In other words, pressure ulcers are inflammation or damage to the skin caused by external physical pressure (e.g., one's own body weight), and develop when sufficient oxygen and nutrients are not distributed to skin cells that are compressed for a long time. In addition, skin cells in the area of pressure ulcers undergo apoptosis, causing a loss of tissue homeostasis, and as the condition progresses and worsens, hypoproteinemia may occur due to leakage of body fluids. Alternatively, inflammation may progress and worsen, causing the formation of blisters or abscesses. In addition to pressure, repeated irritation such as friction and shearing can damage the skin, and harmful bacteria that normally reside on the surface of the skin may become present in the wound and infect it, causing a bacterial infection.
[0020] Furthermore, kestose, which is an active ingredient of this embodiment, is a trisaccharide oligosaccharide in which one molecule of fructose is bound to sucrose. There are three types of kestose, namely 1-kestose, 6-kestose, and neokestose, depending on the binding position of fructose. "Kestose" in all embodiments of the present invention means a trisaccharide oligosaccharide in which one molecule of fructose is bound to sucrose, and includes 1-kestose, 6-kestose, and neokestose.
[0021] Kestose can be industrially produced, for example, by carrying out an enzymatic reaction using sucrose as a substrate and an enzyme as disclosed in Patent Document 2: JP-A-201980 / 1983. As an example, first, β-fructofuranosidase is added to a sucrose solution, and the solution is allowed to stand at 37°C to 50°C for about 20 hours to carry out the enzymatic reaction, thereby obtaining an enzyme reaction solution. Since this enzyme reaction solution is a sugar solution containing a considerable amount of 1-kestose, it may be used as it is as a formulation component according to this embodiment.
[0022] Alternatively, the enzyme reaction solution can be subjected to a chromatographic separation method as disclosed in Patent Document 3: JP-A-2000-232878 to separate and purify 1-kestose from other sugars (glucose, fructose, sucrose, and tetrasaccharide or higher oligosaccharides, etc.), thereby obtaining a relatively high-purity 1-kestose solution. This solution may be used as a formulation component according to this embodiment. Alternatively, the 1-kestose solution can be concentrated and then crystallized by a crystallization method as disclosed in Patent Document 4: JP-B-6-70075 to obtain 1-kestose crystals or a composition containing 1-kestose with a purity of 98% by mass or more. This crystal or composition may be used as a formulation component according to this embodiment. Note that the "purity" referred to here means the mass % of 1-kestose in the total mass of sugars.
[0023] In addition, since commercially available fructooligosaccharides contain kestose, they may be used as they are as a formulation component according to the present embodiment. Alternatively, 1-kestose may be purified from commercially available fructooligosaccharides by the above-mentioned method, or may be further crystallized, and the like may be used as a formulation component. Of course, since commercially available kestose also exists, it may be used as a formulation component as it is.
[0024] Furthermore, since kestose is also contained in small amounts in vegetables, fruits, grains, etc. such as onions, garlic, bananas, barley, and rye, extracts from these plants containing kestose may also be used as a formulation component in this embodiment.
[0025] 1-kestose can be analyzed by a method suitable for the condition of the analytical sample among commonly known analytical methods, and a method usually selected by a person skilled in the art depending on the condition of the analytical sample can be used. In a common method, the content of 1-kestose can be analyzed by dissolving the analytical sample in water, or diluting a liquid sample with water as necessary, and subjecting it to high performance liquid chromatography (HPLC) to analyze the sugar composition. The content of 1-kestose can also be calculated by taking the ratio of the peak area in the chromatogram as the mass ratio.
[0026] The present inventors have found a new efficacy of kestose in suppressing bedsores. That is, in an experiment using bedsore model mice to which skin pressure was applied for 24 hours, the quantified bedsore area value on the first day after the skin pressure was released was significantly smaller in a group of mice fed with a feed containing kestose, compared with a control group fed with a control feed (see Example 1-1). This is a new finding of a novel efficacy that kestose exerts an inhibitory effect on exogenous skin diseases such as bedsores by ingestion, while the inhibitory effect of kestose on endogenous skin diseases such as atopic dermatitis has been known in the past. Therefore, as a technical idea based on this finding, the first embodiment is embodied in a traumatic skin disease inhibitor containing kestose as an active ingredient. Furthermore, in the tests conducted, kestose was ingested before the onset of bedsores and showed an inhibitory effect on the onset of bedsores at the onset stage. Considering this, as a sub-concept of the first embodiment, it can also be applied as an agent that is ingested or administered before the onset of traumatic skin diseases, i.e., an agent for inhibiting the onset of traumatic skin diseases or an agent for preventing traumatic skin diseases.
[0027] In addition, regarding the suppressive effect on bedsores, a new effect of kestose on promoting the production of skin collagen in the bedsore area was found. That is, in the specimens stained with Masson's trichrome from tissue sections taken from the bedsore area of the above-mentioned bedsore model mice one day after the skin pressure was released, the spread of skin collagen (collagen fibers) was observed to be interrupted in the control group fed with the control feed, whereas the skin collagen (collagen fibers) was observed to be formed over a wider area without interruption in the mouse group fed with the feed containing kestose (Example 1-2).
[0028] Skin collagen is known to decrease not only due to chronic decrease with aging, but also due to skin stress caused by ultraviolet rays, dry skin, etc., and can be said to be one of the indicators of skin robustness. In addition, when the dermis or subcutaneous tissue is lost due to a wound such as a bedsore, it is repaired by proliferation of fibroblasts and granulation tissue containing a large amount of collagen fibers, and a scar is formed. Therefore, it is considered that promotion of collagen production in the bedsore area leads to the alleviation and improvement of the bedsore, and also leads to the inhibition of the progression and worsening of the bedsore. For this reason, the traumatic skin disease inhibitor according to the first embodiment can be applied as a skin collagen production promoter as a subordinate concept. The "skin collagen production promoting effect" referred to here includes the effect of promoting the production of skin collagen, inhibiting the decrease in the amount of the skin collagen, and the effect of increasing the amount of the skin collagen.
[0029] In addition, regarding the suppressive effect of bedsore, the suppressive effect of kestose on the apoptosis of skin cells in the bedsore area was newly found. That is, in the specimens obtained by TUNEL staining of tissue sections taken from the bedsore area of the above-mentioned bedsore model mouse one day after the skin pressure was released, in the mouse group fed with food containing kestose, apoptosis of skin cells hardly occurred even in the compressed area, and the staining state was almost the same as that of the adjacent normal skin area (see Example 1-3). As mentioned above, apoptosis of cells in the bedsore area is a phenomenon that causes the progression and aggravation of bedsores, so it is thought that suppression of apoptosis leads to suppression of bedsores. For this reason, the traumatic skin disease inhibitor according to the first embodiment can be applied as an apoptosis inhibitor of skin cells as a subordinate concept. The "suppressive effect of apoptosis of skin cells" here includes the effect of suppressing an increase in the number of skin cells that undergo apoptosis and the effect of reducing the number of the skin cells.
[0030] In addition, regarding the suppressive effect on bedsores, the effect of kestose on improving the diversity of skin bacterial flora was newly discovered. That is, as a result of genetic analysis of DNA samples taken from the bedsores of the above-mentioned bedsore model mice, the Shannon index, which indicates the alpha diversity that represents the species diversity of the bacterial flora, tended to be higher in the group of mice fed food containing kestose, compared to the control group fed the control food, on days 0, 1, and 7 after the release of pressure (see Example 2-1).
[0031] Skin surface has a skin flora inhabited by many resident bacteria. The diversity of the skin flora represents the health of the skin. As an example, Patent Document 5: JP 2021-040517 A describes that if the balance of the skin flora is disturbed, the resistance of the skin is weakened, and normally harmless bacteria can lead to inflammation, rashes, and the like. As an example, Patent Document 6: JP 2020-094047 A describes that in the pathological area of atopic dermatitis, the diversity of the skin flora is reduced and the proportion of Staphylococcus aureus, a harmful bacterium, is increased. Therefore, it is believed that improving the diversity of the skin flora in the bedsore area leads to the suppression of bedsores. For this reason, the traumatic skin disease inhibitor according to the first embodiment can be applied as a skin flora diversity enhancer as a subordinate concept.
[0032] Furthermore, the above genetic analysis revealed that the relative occupancy rate of multiple types of harmful bacteria causing infectious diseases was significantly lower in the group of mice fed with feed containing kestose compared to the control group fed with control feed (see Example 2-2). The harmful bacteria are bacteria of the genus Streptococcus, Staphylococcus, and Pseudomonas, which are recognized as carriers and infections in traumatic skin disease sites such as bedsores and are thought to be involved in the progression and aggravation of the disease. These genera include, for example, species that are subject to infection control in hospitals, such as Streptococcus pyogenes, Staphylococcus aureus, and Pseudomonas aeruginosa, and are broadly considered to be harmful bacteria in skin diseases, regardless of whether they are exogenous or endogenous.
[0033] This finding is a new discovery of a novel efficacy that the growth of harmful skin bacteria can be controlled by orally ingesting kestose, an oligosaccharide that can be added to food as a food composition. Therefore, as a technical idea based on this finding, the second embodiment is embodied in an inhibitor of the growth of harmful skin bacteria containing kestose as an active ingredient. Kestose and its manufacturing method, etc., referred to here are as explained in the first embodiment. It can also be said that the second embodiment is a technical means for solving the problem of providing an agent that can inhibit the growth of harmful skin bacteria using a substance that can be added to food as a food composition. The "inhibitory effect of the growth of harmful skin bacteria" referred to here includes the effect of inhibiting an increase in the number of harmful skin bacteria and the effect of reducing that number.
[0034] Furthermore, the term "harmful skin bacteria" as used herein refers to bacteria that are found to be carried or transmitted in diseased skin areas and are thought to be involved in the progression or worsening of the disease, and includes bacteria of the genera Streptococcus, Staphylococcus, and Pseudomonas.
[0035] Examples of harmful bacteria in the genus Streptococcus include Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, etc. Examples of harmful bacteria in the genus Staphylococcus include Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA), etc. Examples of harmful bacteria in the genus Pseudomonas include Pseudomonas aeruginosa, etc.
[0036] Furthermore, in a specimen obtained by staining tissue sections taken from normal skin, which is healthy skin without skin disease, with Masson's trichrome staining, it was found that the quantified collagen fiber range value was significantly larger in a mouse group fed with a feed containing kestose than in a control group fed with a control feed (Example 3). As a result, based on this finding in normal skin and the above-mentioned finding in bedsores, it was newly discovered that kestose has the effect of promoting the production of skin collagen regardless of the presence or absence of skin disease. Therefore, as a technical idea based on this finding, the third embodiment is embodied in a skin collagen production promoter containing kestose as an active ingredient. The kestose and the manufacturing method thereof, etc., referred to here are as described in the first embodiment. The third embodiment is not limited to the suppression of traumatic skin diseases, but can also be applied, for example, as anti-aging or to the reduction of skin collagen due to skin stress. In other words, it can be said to be a technical means for solving the problem of providing an agent that can promote the production of skin collagen regardless of the skin condition for a wide range of purposes such as medical care, beauty, health, and anti-aging. The "effect of promoting skin collagen production" as used herein includes the effect of suppressing a decrease in the amount of skin collagen, and the effect of increasing that amount.
[0037] The effective dose of the traumatic skin disease inhibitor according to the first embodiment, the harmful skin bacteria growth inhibitor according to the second embodiment, and the harmful skin bacteria growth inhibitor according to the third embodiment (hereinafter, the present agent) for humans is 0.45 to 0.76 (g / kg body weight / day) as kestose. However, as described above, kestose is also contained in foods that humans ingest on a daily basis, is a substance that has been eaten since ancient times, and has high safety because no toxicity or mutagenicity has been found in toxicity tests and genotoxicity tests (Non-Patent Document 1: Food and Development, Vol. 49, No. 12, p. 9). Therefore, an amount exceeding the above-mentioned dosage may be administered (ingested). In addition, the present agent may be administered (ingested) once or in multiple divided doses per day. From the above, the present agent is preferably administered (ingested) to humans at a dose of at least 0.45 to 0.76 (g / kg body weight / day) as kestose.
[0038] The above dosage was calculated based on the examples using the model mice described below, in which the action and effect of the drug was confirmed. That is, using the published average daily food intake of mice: about 3 to 5 g (https: / / www.eptrading.co.jp / service / researchdiets / s02.html), the daily intake of kestose was calculated to be 0.15 to 0.25 g from the "kestose-containing feed" in which 1-kestose was mixed at 5% by mass of the total feed, which was fed ad libitum in each example. Next, for the 12-week-old male C57BL / 6J model mice used in each example, the published average body weight of the same strain, sex, and age (26.7 g) was used (https: / / www.jax.or.jp / cms / jaxweb / pdf / product / rm / information / b6j / Body_weight_B6J_2009.pdf) to calculate the dosage of kestose to the mice in the examples: 5.6179 to 9.3632 (g / kg body weight / day). Next, in accordance with the FDA guidelines (US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), "Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers," July 2005.), the dose to be administered to the mice was divided by a conversion factor of 12.3 to calculate the dose to be administered to humans: 0.4567 to 0.7612 (g / kg body weight / day).
[0039] The present agent also includes a formulation appropriately prepared with kestose as an active ingredient. That is, the present agent includes a formulation consisting of kestose alone, and a formulation consisting of kestose and ingredients other than kestose. Examples of ingredients other than kestose include impurities contained in the substrate of the enzyme reaction in the manufacturing process of kestose, sugars such as glucose, fructose, sucrose, tetrasaccharide nystose, and pentasaccharide fructofuranosyl nystose remaining as intermediate products or by-products in the manufacturing process of kestose, nutrients such as dietary fiber, polyphenols, amino acids, proteins, lipids, vitamins, vitamin-like substances, and minerals that are blended in the formulation, and additives such as excipients, binders, lubricants, colorants, disintegrants, thickeners, preservatives, stabilizers, and pH adjusters that are added for the purpose of forming into a specific dosage form. Since kestose is a prebiotic, the present agent can also be configured to have a function as a prebiotic in addition to the specific function according to each embodiment. Therefore, as an example, the present agent can be formulated as a preparation in which kestose is combined with other prebiotics or probiotics.
[0040] In addition, the dosage form of the present agent is not limited, and for example, it can be appropriately formed into oral solid preparations (including supplements) such as tablets, granules, powders, and capsules, oral liquid preparations such as oral liquids and syrups, and parenteral liquid preparations such as injections. In addition, an appropriate drug delivery system (DDS) may be applied. Each dosage form can be appropriately formed by a method known to those skilled in the art. In addition, the administration method of the present agent is not limited, and oral administration, intravenous administration, intraperitoneal administration, intradermal administration, sublingual administration, local administration, etc. can be appropriately selected for humans or mammals other than humans.
[0041] In addition, the agent itself can be applied as a medicine, a cosmetic, a food, etc. Alternatively, the agent can be applied as a pharmaceutical composition, a cosmetic composition, a food composition, etc. That is, when the agent is applied as a composition, it can take the form of a medicine, a cosmetic, a food, etc. in which the agent is blended as a composition. In other words, it can take the form of a medicine, a cosmetic, a food, etc. containing the agent as a composition. The term "medicine" as used herein means any product intended to be used for the treatment or prevention of diseases in humans or mammals other than humans, and includes medicines and quasi-drugs under the law (in Japan, the Law Concerning the Ensuring of Quality, Effectiveness and Safety of Pharmaceuticals, Medical Devices, etc.). The term "food" as used herein means any product that is eaten or drunk, including beverages. When the agent is applied as a food or food composition, the food that is the agent or the food that contains the agent can be applied as a food to be taken for the purpose of a specific health function according to each embodiment. That is, in the case of Japan, it may be applied as a product that displays or claims a specific health function, such as a food for specified health uses under the Health Promotion Act or a food with functional claims under the Food Labeling Act.
[0042] In addition, the form of the product containing the agent as a composition is not limited. That is, like the agent, pharmaceuticals, cosmetics, foods, etc. containing the agent as a composition may also be in the form of oral solid preparations (including supplements) such as tablets, granules, powders, capsules, etc., oral liquid preparations such as oral liquids and syrups, and parenteral liquid preparations such as injections. Therefore, preparations consisting of kestose and components other than kestose may be considered to be the agent itself and may also be considered to be preparations containing the agent as a composition.
[0043] Furthermore, as mentioned above, kestose has high safety as a food ingredient. In addition, kestose has extremely low hygroscopicity, excellent solubility and heat resistance, so it is highly convenient for food processing, and it has a sweetness similar to that of sugar, so it can be used as a sugar substitute. Taking advantage of these properties of kestose, foods containing the agent as a composition can be suitably applied as various foods such as gums, gummies, candies and other confectioneries, flake-shaped or puff-shaped cereals, bars, jellies, swallowable foods, beverages, etc., containing kestose. EXAMPLES
[0044] (Example 1-1) After acclimatization, 12-week-old male C57BL / 6J mice (CLEA Japan, Inc.) were divided into a control group and an example group of three mice each. In the test feeding, the control group was fed the standard purified feed "AIN-93G" (CLEA Japan, Inc.) as a control feed. Meanwhile, the example group was fed a "kestose-containing feed" in which a part of the cornstarch in the "AIN-93G" was replaced with commercially available 1-kestose (iKes Crystal (iKes is a registered trademark), purity 95% by mass, Itochu Sugar Co., Ltd.) so that 1-kestose was mixed in 5% by mass of the total mass of the feed. The mice were kept in the same breeding room throughout the entire period, in a breeding environment of 23°C to 25°C, 50% to 60% humidity, 12 hours of light and 12 hours of dark, one mouse per cage, with free access to water and food.
[0045] After 7 days of acclimation and 14 days of test breeding, the backs of the mice were depilated, and the depilated skin was pinched with magnets from both sides and compressed for 24 hours, after which the magnets were removed. The skin findings of both groups of bedsore model mice thus created were observed for 7 days (the day skin pressure was released was counted as day 0) after pressure was released (after the magnets were removed). Based on the image data of the bedsore area that appeared, the size of the bedsore area (bedsore area) was quantified using analysis software (ImageJ). Figure 1 shows the average quantified bedsore area for both groups on the first day after skin pressure was released.
[0046] As shown in Figure 1, the value of the bedsore area was significantly smaller in the Example group than in the Control group on the first day after the pressure was released. In addition, in the observation on the seventh day after the pressure was released, scarring of the bedsore area was observed in the Example group, and alleviation and improvement of the bedsore area was confirmed (not shown).
[0047] (Example 1-2) In addition, a test system was set up in the same manner as in Example 1-1, and specimens were prepared by staining tissue sections taken from the ulcer site one day after the release of pressure on both groups of bedsore model mice with Masson's trichrome staining, which allows visual distinction between collagen fibers and other tissue components. Figure 2A shows an electron microscope image of the specimen in the control group, and Figure 2B shows an electron microscope image of the specimen in the example group.
[0048] According to Masson's trichrome staining, collagen fibers are stained blue, while cytoplasm is stained red. In the patent drawings, the colors are distinguished by the shade of color, with relatively light staining corresponding to collagen fibers (original blue) and relatively dark staining corresponding to cytoplasm (original red). As shown in FIG. 2A, in the control group, both the left and right ends of the photograph are lightly stained as collagen fibers, but in the area surrounded by the dashed line in the center, the upper side is darker stained as cytoplasm, and the lower side is unstained. That is, a state in which the spread of dermal collagen (collagen fibers) was interrupted was observed, and a state presumed to be a decrease (deficiency) of dermal collagen was observed. In contrast, as shown in FIG. 2B, in the example group, a state in which lightly stained dermal collagen (collagen fibers) was formed over a wider area without interruption was observed.
[0049] (Examples 1-3) Furthermore, a test system was set up in the same manner as in Example 1-1, and specimens were prepared from tissue sections taken from the ulcer site on the first day after pressure was released from both groups of bedsore model mice, and the tissues and cells that underwent apoptosis were stained with Tunel staining. Figure 3A shows an electron microscope image of the specimen from the control group, and Figure 3B shows an electron microscope image of the specimen from the example group.
[0050] In the patent drawings, the staining by the Tunnell method is distinguished by the shade of color, and the tissues and cells that have undergone apoptosis appear as relatively dark staining. As shown in FIG. 3A, in the control group, the spread of dark staining is observed at the compression site (especially the upper left part), which is not seen in the adjacent normal skin site. This shows that the progression of the bedsore significantly induces apoptosis of skin cells at the compression site. In contrast, as shown in FIG. 3B, in the example group, the dark staining seen at the compression site of the control group was hardly observed in either the normal skin site or the compression site, and the staining state was almost the same between the compression site and the normal skin site. This shows that the apoptosis of skin cells at the compression site was almost not occurring, just like in the normal skin site. EXAMPLES
[0051] (Example 2-1) A test system was set up in the same manner as in Example 1-1, and the diversity of the skin microbiota on days 0, 1, and 7 after the release of pressure was analyzed for both groups of bedsore model mice by calculating and comparing the Shannon index, which indicates alpha diversity, which represents species diversity, by amplicon sequence analysis. First, a DNA sample was collected from the bedsore area using a swab (4N6 FLOQ Swabs (FLOQ is a registered trademark), COPAN Diagnostics). After the cotton ball at the tip of the swab was moistened with the preservative solution in a 2 mL tube, the cotton ball was used to wipe the bedsore area evenly about 10 times, and then the cotton ball was inserted into the preservative solution in the tube, the handle of the swab was broken off at the break point, the lid of the tube containing the cotton ball was closed, and a sample solution was collected. Next, the sample solution was placed in a dedicated 2 mL tube (TM-626), and furthermore, dedicated crushing beads (ZSB-01) containing zirconia and silica were placed in the tube. Then, using a bead-type cell crusher (MS-100R, Tommy Seiko Co., Ltd.), the crushing process of "500 rpm, 1 minute crushing operation, 30 seconds stop" was performed three times, and then the beads were dropped by centrifugation at RCF 10,000 × g for 1 minute. The thus obtained supernatant (200 μL) was subjected to DNA extraction. DNA extraction was performed using a kit (QIAamp DNA Mini Kit (QIAamp is a registered trademark), QIAGEN GmbH) according to the attached protocol.
[0052] Next, the extracted DNA was subjected to PCR using primers that amplify the V3-V4 region of the 16SrRNA gene, followed by amplicon sequence analysis to analyze the diversity of the skin bacterial flora in the bedsore area. PCR and amplicon sequence analysis were performed at the request of Seibu Giken Co., Ltd. PCR was performed using the extracted DNA as template DNA, forward primer (V3V4f_q: 5'-CCTACGGGNGGCWGCAG-3') (referred to as "SEQ ID NO: 1") and reverse primer (V3V4r_q: 5'-GACTACHVGGGTATCTAATCC-3') (referred to as "SEQ ID NO: 2") designed from a sequence homologous to the 16SrRNA gene, and TaKaRa Ex-taq (TaKaRa is a registered trademark) (Takara Bio Inc.) as the PCR enzyme. The reaction program consisted of an initial denaturation step at 94°C for 2 min, followed by 20 cycles of thermal denaturation at 94°C for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 30 s, with a final extension step at 72°C for 5 min.
[0053] 20 μL of the amplified product obtained by PCR was analyzed using a next-generation sequencer (MiSeq System (MiSeq is a registered trademark), Illumina) and sequencing was performed. Furthermore, the obtained sequence data was analyzed using the microbial flora analysis pipeline: QIIME2 (Quantitative Insights into Microbial Ecology 2) version 2022.2. After quality filtering and noise removal using the QIIME2 software package DADA2 (Divisive Amplicon Denoising Algorithm 2), the output sequences were assigned to taxonomic groups using "Silva 138 SSU Ref NR 99" as the reference sequence. Then, the sampling depth was set to the minimum number of reads per sample to calculate the Shannon index. The Shannon index (median) of each group is shown in Table 1.
[0054] [Table 1]
[0055] The Shannon index, which indicates α diversity, which represents species diversity, indicates that the higher the value, the higher the species diversity. As shown in Table 1, in the example group, the Shannon index tended to be higher than in the control group on days 0, 1, and 7 after the pressure was released.
[0056] (Example 2-2) In addition, the relative occupancy rates of several types of specific genera of bacteria were compared between the two groups by the above analysis. The relative occupancy rates (median) of each group are shown in Table 2.
[0057] [Table 2]
[0058] The Streptococcus, Staphylococcus, and Pseudomonas bacteria compared here are all harmful bacteria that are found to be carried and infected in traumatic skin disease sites, including bedsores, and are thought to be involved in the progression and worsening of the disease. As shown in Table 2, in the example group, the relative occupancy rate of Streptococcus bacteria was lower on the 0th, 1st, and 7th days after pressure release compared to the control group. In addition, the relative occupancy rate of Staphylococcus bacteria was significantly lower on the 1st and 7th days after pressure release. In addition, the relative occupancy rate of Pseudomonas bacteria was significantly lower on the 7th day after pressure release. EXAMPLES
[0059] After acclimatization, 12-week-old male C57BL / 6J mice (CLEA Japan, Inc.) were divided into a control group and an example group of 5 mice each. In the test feeding, the control group was fed the standard purified feed "AIN-93G" (CLEA Japan, Inc.) as a control feed. Meanwhile, the example group was fed a "kestose-containing feed" in which a part of the cornstarch in the "AIN-93G" was replaced with commercially available 1-kestose (iKes crystal, purity 95% by mass, Itochu Sugar Co., Ltd.) so that 1-kestose was mixed in 5% by mass of the total feed. The mice were kept in the same breeding room throughout the entire period, in a breeding environment of 23°C to 25°C, 50% to 60% humidity, 12 hours of light and 12 hours of dark, one mouse per cage, with free access to water and food.
[0060] After 7 days of acclimation and 14 days of test breeding, tissue sections taken from normal skin (healthy skin without skin disease) on the back of the mice were stained with Masson's trichrome to prepare specimens. The area of collagen fibers identified by staining was quantified based on image data using analysis software (cellSens Dimension (cellSens is a registered trademark), Evident Co., Ltd.). The thickness of the dermis where the identified collagen layer is formed was also measured using the same software. Figure 4A shows the average value of the quantified collagen fiber area for both groups. Figure 4B shows the average value of the measured dermal thickness for both groups.
[0061] As shown in Figure 4B, there is almost no difference in dermis thickness between the control group and the example group, so by comparing the collagen fiber range shown in Figure 4A between the two groups, it is possible to practically compare the collagen production amounts of the two groups. And, as shown in Figure 4A, the collagen fiber range value was significantly larger in the example group compared to the control group. Therefore, the results of Examples 1-2 and 3 demonstrated the collagen production promoting effect of kestose regardless of the presence or absence of skin disease (irrespective of skin condition).
[0062] The above-described embodiment encompasses the following technical ideas. (Aspect 1) Kestose for use as an inhibitor of traumatic skin disease.
[0063] (Aspect 2) Kestose for use as an inhibitor of the growth of harmful skin bacteria.
[0064] (Aspect 3) Kestose for use as a skin collagen production promoter.
[0065] (Aspect 4) A traumatic skin disease inhibitor containing kestose.
[0066] (Aspect 5) An inhibitor of the proliferation of harmful skin bacteria containing kestose.
[0067] (Aspect 6) A skin collagen production promoter containing kestose.
[0068] (Aspect 7-1) A method for suppressing traumatic skin diseases using kestose.
[0069] (Aspect 7-2) Suppressing traumatic skin diseases by suppressing apoptosis of skin cells using the kestose A method for suppressing traumatic skin diseases according to (Aspect 7-1), characterized by:
[0070] (Aspect 7-3) Suppression of traumatic skin diseases by improving the diversity of skin microbiota using the kestose A method for suppressing traumatic skin diseases according to (Aspect 7-1), characterized by:
[0071] (Aspect 7-4) Suppression of traumatic skin diseases by promoting the production of skin collagen using the above kestose A method for suppressing traumatic skin diseases according to (Aspect 7-1), characterized by:
[0072] (Aspect 7-5) The kestose is administered before the onset of a skin disease. A method for suppressing traumatic skin diseases according to (Aspect 7-1), characterized by:
[0073] (Aspect 7-6) Orally administering an effective amount of the kestose to a human or a non-human mammal in need of suppression of a traumatic skin disease. A method for suppressing traumatic skin diseases according to (Aspect 7-1), characterized by:
[0074] (Aspect 7-7) Orally administering 0.45 to 0.76 (g / kg body weight / day) of the kestose to a human in need of suppression of a traumatic skin disease. A method for suppressing traumatic skin diseases according to (Aspect 7-1), characterized by:
[0075] (Aspect 8-1) A method for inhibiting the growth of harmful skin bacteria using kestose.
[0076] (Aspect 8-2) Orally administering an effective amount of the kestose to a human or a non-human mammal in need of inhibiting the proliferation of harmful skin bacteria. A method for inhibiting the proliferation of harmful skin bacteria described in (Aspect 8-1), characterized by:
[0077] (Aspect 8-3) Orally administering 0.45 to 0.76 (g / kg body weight / day) of the kestose to a human in need of inhibiting the proliferation of harmful skin bacteria. A method for inhibiting the proliferation of harmful skin bacteria described in (Aspect 8-1), characterized by:
[0078] (Aspect 9-1) A method for promoting skin collagen production using kestose.
[0079] (Aspect 9-2) Orally administering an effective amount of the kestose to a human or a non-human mammal in need of promoting the production of skin collagen. A method for promoting skin collagen production according to (Aspect 9-1), characterized by:
[0080] (Aspect 9-3) Orally administering 0.45 to 0.76 (g / kg body weight / day) of the kestose to a human in need of promoting skin collagen production. A method for promoting skin collagen production according to (Aspect 9-1), characterized by:
[0081] (Aspect 10) Use of kestose to suppress traumatic skin diseases.
[0082] (Aspect 11) Use of kestose to inhibit the growth of harmful skin bacteria.
[0083] (Aspect 12) Use of kestose to promote the production of skin collagen.
[0084] (Aspect 13) Use of kestose for the manufacture of an agent for suppressing traumatic skin diseases.
[0085] (Aspect 14) Use of kestose for the manufacture of an inhibitor of the proliferation of harmful skin bacteria.
[0086] (Aspect 15) Use of kestose for the manufacture of a skin collagen production promoter.
Claims
1. A traumatic skin disease inhibitor containing kestose as an active ingredient.
2. Inhibitor of apoptosis in skin cells 2. The traumatic skin disease inhibitor according to claim 1, characterized in that
3. It enhances the diversity of skin microbiota 2. The traumatic skin disease inhibitor according to claim 1, characterized in that
4. It is a skin collagen production promoter.
2. The traumatic skin disease inhibitor according to claim 1, characterized in that
5. Inhibitor of traumatic skin disease The traumatic skin disease inhibitor according to any one of claims 1 to 4, characterized in that
6. A medicine, cosmetic, or food, comprising the traumatic skin disease inhibitor according to any one of claims 1 to 4.
7. An inhibitor of the growth of harmful skin bacteria, containing kestose as the active ingredient.
8. A medicine, cosmetic, or food product comprising the inhibitor of proliferation of harmful skin bacteria according to claim 7.
9. A skin collagen production promoter with kestose as its active ingredient.
10. A medicine, cosmetic, or food product comprising the skin collagen production promoter according to claim 9.
Citation Information
Patent Citations
Substance for promoting propagation of lactobacillus bifidus
JP1983201980A
Integrated collection method of typed data and optically scanned data for interface in computer and station for it
JP1994070075A
Fructosyltransferase and fractional production of 1- kestose and nystose using the enzyme
JP2000232878A
Allergy-inhibiting composition, allergy-inhibiting food, and allergy inhibitor
JP2006321786A
Agents for improving or variegating normal bacterial flora of skin and compositions containing the same
JP2020094047A
